Adaptin BIO
OTC: APTNCharlotte, US · Founded 2022 · Delaware corporation
Adapt Biotechnologies develops the BRiTE platform, a bispecific antibody technology designed to treat brain tumors and intracerebral malignancies by activating T cells to target and destroy glioma cells. The platform combines manipulated T cells with bispecific antibodies to deliver targeted therapy to brain tissue.
Founders & leadership
TM
Timothy ManessChief Financial Officer
LA
L. Arthur HewittChief Development Officer
MR
Michael RobertsPresident and Chief Executive Officer
SP
Simon PedderExecutive Chairman
Board
AZ
Anthony ZookBoard director
JN
J. Nick RiehleBoard director
PG
Patrick GallagherBoard director
Reported raises · per SEC filings
Form D private placements$15M disclosed across 2 rounds · 2025
▶$1.9MraisedJun 2026 · 19 investors · BiotechnologyRule 506(b)
▶$1.9MraisedJun 2026 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- L. Arthur HewittExecutive Officer
- Patrick GallagherDirector
- Michael RobertsExecutive Officer, Director
- J. Nick RiehleDirector
- Anthony ZookDirector
- Timothy ManessExecutive Officer
- Simon PedderExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $1.9M
- Sales commissions
- $229.4K
- Placement agents
- Laidlaw & Company (UK) Ltd.
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$13.1MraisedFeb 2025 · 95 investors · BiotechnologyRule 506(b)
▶$13.1MraisedFeb 2025 · 95 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Timothy ManessExecutive Officer
- Anthony ZookDirector
- J. Nick RiehleDirector
- L. Arthur HewittExecutive Officer
- Michael RobertsExecutive Officer, Director
- Simon PedderExecutive Officer, Director
- Patrick GallagherDirector
- Offering amount
- $23.4M
- Amount sold
- $13.1M
- Sales commissions
- $475.6K
- Placement agents
- Laidlaw & Company (UK) Ltd.
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
IQVIA10 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Precision BioSciences9 shared keywordsPrecision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
Bioworld8 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Adaptin BIO for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Adaptin BIO do?
- Adapt Biotechnologies develops the BRiTE platform, a bispecific antibody technology designed to treat brain tumors and intracerebral malignancies by activating T cells to target and destroy glioma cells. The platform combines manipulated T cells with bispecific antibodies to deliver targeted therapy to brain tissue.
- How much funding has Adaptin BIO raised?
- Adaptin BIO has disclosed $15M raised across 2 rounds.
- Where is Adaptin BIO headquartered?
- Adaptin BIO is headquartered in Charlotte, US.